Using CCR5 immunotoxins to help eliminate HIV reservoirs
Official title: CCR5 immunotoxins as components of HIV cure regimens
Funded at Tendel Therapies INC. · NIH-10664839 · Data updated 2026-11-12
This study is exploring a new way to help people with HIV by using a special treatment that targets and removes the cells where the virus hides, especially early on in the infection, with the hope of finding a lasting cure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tendel Therapies INC. NIH-funded |
| Lab location | 1 site (Kensington, United States) |
| Project start | July 13, 2022 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $300,000 |
| NIH project number | 5R41AI165350-02 |
| Project ID | NIH-10664839 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults living with HIV, particularly those in the early stages of infection.
✕Less likely to help
Patients who are not infected with HIV or those with advanced stages of the disease may not benefit from this research.
What this research studies
This research investigates the use of CCR5 immunotoxins as a method to deplete HIV reservoirs in the body, which is crucial for developing effective cure strategies for HIV. The approach focuses on directly targeting and eliminating cells that harbor the virus, particularly during early infection when these cells are most prevalent. By employing a bispecific antibody that targets CCR5, the research aims to demonstrate the potential for achieving a functional or even sterilizing cure for HIV. Patients may benefit from this innovative strategy if it proves successful in reducing or eliminating the virus from their systems.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking method for curing HIV by effectively eliminating the virus from the body.
How similar studies have gone: Previous research has shown promise in similar approaches, particularly in animal models, indicating potential for success in human applications.
Where this research is happening
-
Tendel Therapies INC.
Kensington, United States Active
Researchers
- Principal investigator: Hartigan-O'connor, Dennis J. — Tendel Therapies INC.
- Study coordinator: Hartigan-O'connor, Dennis J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.